Close
Achema

Australian Cell Graft For Nervous System Gets Funding Boost

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Griffith University, based in Australia, has gone on to conduct a world-first study when it comes to cell transplantation so as to repair nervous system injuries and has thus received a tremendous boost of a $5.4 million fund extension from the Motor Accident Insurance Commission.

Professor James St. John, who happens to head the Griffith’s Clem Jones Centre for Neurobiology and Stem Cell Research, has confirmed that they are coming up with cell transplantation therapies in order to treat injuries that are related to the nervous system.

The research team, under the guidance of Professor John, has gone on to develop a world-first cellular nerve bridge, which has already received a couple of major national awards, namely the NHMRC Marshall and Warren Innovation Award for 2019 and the Research Australia Discovery Award for 2020–21.

The latest round of funding is going to allow the research team at Griffith to expand the horizons of the nerve build technology to a range of nervous system injuries that happen to be wider, including brain as well as peripheral nerve injuries.

It is well to be noted that the new MAIC funding, which will be worth $5.4 million, will add up to a total investment from MAIC to the tune of $16 million since 2017, with the prime focus being on the development of a therapy related to spinal cord injury.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back